94 related articles for article (PubMed ID: 22576694)
21. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
van der Wilt CL; Kuiper CM; Peters GJ
Oncol Res; 1999; 11(8):383-91. PubMed ID: 10803742
[TBL] [Abstract][Full Text] [Related]
22. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
23. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
[TBL] [Abstract][Full Text] [Related]
24. Cell cycle regulation of the G0/G1 transition in 5-fluorouracil-sensitive and -resistant human colon cancer cell lines.
McGinn CJ; Pestalozzi BC; Drake JC; Glennon MC; Kunugi K; Otterson G; Allegra CJ; Johnston PG; Kinsella TJ
Cancer J; 2000; 6(4):234-42. PubMed ID: 11038143
[TBL] [Abstract][Full Text] [Related]
25. Glucose transporter protein-independent tumor cell accumulation of fluorine-18-AFDG, a lipophilic fluorine-18-FDG analog.
Waki A; Fujibayashi Y; Magata Y; Yokoyama A; Sadato N; Tsuchida T; Ishii Y; Yonekura Y
J Nucl Med; 1998 Feb; 39(2):245-50. PubMed ID: 9476929
[TBL] [Abstract][Full Text] [Related]
26. Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling.
Cooper AC; Fleming IN; Phyu SM; Smith TA
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1523-32. PubMed ID: 25579456
[TBL] [Abstract][Full Text] [Related]
27. Cellular metabolic responses of PET radiotracers to (188)Re radiation in an MCF7 cell line containing dominant-negative mutant p53.
Cheon GJ; Chung HK; Choi JA; Lee SJ; Ahn SH; Lee TS; Choi CW; Lim SM
Nucl Med Biol; 2007 May; 34(4):425-32. PubMed ID: 17499732
[TBL] [Abstract][Full Text] [Related]
28. Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011.
Boyer CR; Karjian PL; Wahl GM; Pegram M; Neuteboom ST
Anticancer Drugs; 2002 Jan; 13(1):29-36. PubMed ID: 11914638
[TBL] [Abstract][Full Text] [Related]
29. Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab.
Cheyne RW; Trembleau L; McLaughlin A; Smith TA
Nucl Med Biol; 2011 Apr; 38(3):339-46. PubMed ID: 21492782
[TBL] [Abstract][Full Text] [Related]
30. [Inhibition of 18F-FDG uptake in glioblastoma cells by FDG and glucose].
Oehr P; Ruhlmann J; Kozak B; Brock H; Thieme D; Rink H
Acta Med Austriaca; 1999; 26(3):101-3. PubMed ID: 10520378
[TBL] [Abstract][Full Text] [Related]
31. Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors.
Rooney PH; Stevenson DA; Marsh S; Johnston PG; Haites NE; Cassidy J; McLeod HL
Cancer Res; 1998 Nov; 58(22):5042-5. PubMed ID: 9823306
[TBL] [Abstract][Full Text] [Related]
32. Predicting tumour response to anti-HER1 therapy using medical imaging: a literature review and in vitro study of [18F]-FDG incorporation by breast cancer cells responding to cetuximab.
Smith TA; Cheyne RW
Br J Biomed Sci; 2011; 68(3):158-66. PubMed ID: 21950209
[TBL] [Abstract][Full Text] [Related]
33. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery.
De Angelis PM; Svendsrud DH; Kravik KL; Stokke T
Mol Cancer; 2006 May; 5():20. PubMed ID: 16709241
[TBL] [Abstract][Full Text] [Related]
34. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.
Schultz RM; Patel VF; Worzalla JF; Shih C
Anticancer Res; 1999; 19(1A):437-43. PubMed ID: 10226579
[TBL] [Abstract][Full Text] [Related]
35. Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy.
Engles JM; Quarless SA; Mambo E; Ishimori T; Cho SY; Wahl RL
J Nucl Med; 2006 Apr; 47(4):603-8. PubMed ID: 16595493
[TBL] [Abstract][Full Text] [Related]
36. 17beta-estradiol augments 18F-FDG uptake and glycolysis of T47D breast cancer cells via membrane-initiated rapid PI3K-Akt activation.
Ko BH; Paik JY; Jung KH; Lee KH
J Nucl Med; 2010 Nov; 51(11):1740-7. PubMed ID: 20956467
[TBL] [Abstract][Full Text] [Related]
37. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling.
Maxwell PJ; Longley DB; Latif T; Boyer J; Allen W; Lynch M; McDermott U; Harkin DP; Allegra CJ; Johnston PG
Cancer Res; 2003 Aug; 63(15):4602-6. PubMed ID: 12907638
[TBL] [Abstract][Full Text] [Related]
38. Glucose transport and apoptosis after gene therapy with HSV thymidine kinase.
Haberkorn U; Altmann A; Kamencic H; Morr I; Traut U; Henze M; Jiang S; Metz J; Kinscherf R
Eur J Nucl Med; 2001 Nov; 28(11):1690-6. PubMed ID: 11702112
[TBL] [Abstract][Full Text] [Related]
39. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
40. Early evaluation for treatment efficacy of 5-fluorouracil and hyperthermia on HCT-116 colon cancer cells by fluorine-18-fluorodeoxyglucose uptake.
Wang ZX; Zhang B; Deng SM; Chen SJ
Chin Med J (Engl); 2012 Feb; 125(4):657-61. PubMed ID: 22490491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
